Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**4-[18F]Fluoroglutamic acid (BAY85-8050)** is a radiolabeled amino acid derivative developed as a positron emission tomography (PET) imaging agent. It consists of fluorine-18 conjugated to L-glutamic acid, which leverages tumor-specific uptake due to high glutaminolytic metabolism in certain tumors. Upon intravenous administration, it accumulates in tumor cells, enabling imaging and assessment using PET. The compound is intended for oncology imaging, specifically for detecting and assessing neoplasms via PET scans. The developer is Bayer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[18F]Fluoroglutamic acid.